Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
Clinical trial NCT03360890 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03360890
- Sponsor
- University of Chicago
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-26
- Primary completion
- 2025-12-05
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.